We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Chlorine Dioxide Versus Saline for Wound Irrigation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01341041
Recruitment Status : Completed
First Posted : April 25, 2011
Last Update Posted : April 25, 2011
Information provided by:

Study Description
Brief Summary:
This research is being done because the investigators are trying to examine the safety and effectiveness of this wound cleaning liquid, CACD (chlorine dioxide). The investigators are trying to see if this liquid has the ability to decrease infection rates and decrease the scarring effects from the healing process. In animal studies, CACD has been shown to decrease scar formation and decrease the risk of wound infections. CACD is also used for the treatment of burns to decrease infection rates and improve wound healing. CACD is not FDA approved for this specific use, but it is FDA and USDA approved for reducing bacterial contamination on meat and food products for human consumption. In addition, an investigational drug (IND) application has been submitted to the FDA for this study. The FDA has approved the use of this solution for this study.

Condition or disease Intervention/treatment Phase
Wound - in Medical Care Biological: chlorine dioxide Biological: saline Early Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 201 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Wound Irrigation: Comparison of Normal Saline With Chlorous Acid Chlorine Dioxide Solution
Study Start Date : August 2004
Primary Completion Date : December 2007
Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: chlorine dioxide
2 arms
Biological: chlorine dioxide
one time wash with 50ppm CD solution
Active Comparator: saline
one time wash with 50-100cc of normal saline
Biological: saline
one time wash with 50-100 cc normal saline

Outcome Measures

Primary Outcome Measures :
  1. cosmesis [ Time Frame: 72 hrs post-ED visit ]
    Cosmesis will be assessed by taking pictures of the wound at presentation, upon receiving sutures, 48-72 hrs later, and 3-4 mths later. At 3-4 mths the patient will rate how well they think the wound healed, via a visual analog scale. At that time, two blinded ER physicians will do this as well. They will also designate a wound evaulation score, based on criteria that will be provided to them. Two blinded plastic surgeons will assess all photographs, visual analog scores. and wound evaluation scores, and provide their own visual analog scale assessment of how well each wound healed.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-100 years old
  • simple laceration requiring irrigation & sutures
  • patient has method of contact
  • patient is willing to return to ED in 3-4 mths

Exclusion Criteria:

  • immunocompromised
  • consult required for repair
  • diabetic
  • require antibiotics
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01341041

United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Rhode Island Hospital
More Information

Responsible Party: Jonathan Valente MD, Rhode Island Hospital
ClinicalTrials.gov Identifier: NCT01341041     History of Changes
Other Study ID Numbers: 0334-03
First Posted: April 25, 2011    Key Record Dates
Last Update Posted: April 25, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Wounds and Injuries
Chlorine dioxide
Dental Disinfectants
Anti-Infective Agents